Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1

Maureen P. Martin(Ragon Institute of MGH, MIT and Harvard), Mary Carrington(Ragon Institute of MGH, MIT and Harvard), Bruce D. Walker(Howard Hughes Medical Institute), David W. Haas(Meharry Medical College), Bernard A. P. Lafont(National Institutes of Health), J.P. Vivian(Monash University), Andrëw G. Brööks(The University of Melbourne), Mark Connors(National Institute of Allergy and Infectious Diseases), Nelson L. Michael(Walter Reed Army Institute of Research), Jonathan M. Carlson(Microsoft (United States)), Patrick R. Shea(Columbia University), Stephen A. Migueles(National Institute of Allergy and Infectious Diseases), Sian Llewellyn‐Lacey(University College London Hospitals NHS Foundation Trust), Zabrina L. Brumme(Simon Fraser University), Qi Ying(Hong Kong University of Science and Technology), Veron Ramsuran(University of KwaZulu-Natal), Rasmi Thomas(Walter Reed Army Institute of Research), Steven G. Deeks(University of California, San Francisco), Emma Gostick(University Hospital of Wales), Jacqueline Widjaja(The University of Melbourne), Phillip Pymm(The University of Melbourne), Vivek Naranbhai(Centre for Human Genetics), Steven M. Wolinsky(Northwestern University), Jamie Rossjohn(Institute of Infection and Immunity), Florencia Segal(Brigham and Women's Hospital), Nicolas Vince(École Centrale de Nantes), James J. Goedert(National Cancer Institute), Jacques Fellay(SIB Swiss Institute of Bioinformatics), David A. Price(University Hospital of Wales), Shu Cheng Wong(The University of Melbourne), Xiaojiang Gao(New York Academy of Medicine), Philippa M. Saunders(The University of Melbourne)
Journal of Clinical Investigation
February 20, 2018
Cited by 63


Related Papers